martedì, 30 maggio 2023
1 Aprile 2017

FDA Panel Supports Subcutaneous Rituximab for Blood Cancers

March 29, 2017 – The FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers, according to Genentech, the manufacturer of the treatment. The company explained in a statement that the novel co-formulation includes the identical monoclonal antibody as intravenous (IV) rituximab, along with the molecule hyaluronidase, which facilitates the delivery of … (leggi tutto)